Gimatecan (sigma-tau industrie farmaceutiche riunite/novartis).
Sigma-Tau Industrie Farmaceutiche Riunite SpA and Novartis AG are developing oral gimatecan, a camptothecin derivative, for the potential treatment of tumors, including glioblastoma.